|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02367 GIANT BIOGENE
Nominal 
38.500 +0.340 (+0.891%) | 2025/06 - Interim RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Cash from / (used in) Operating Activities | -- | 2,041,202 | 1,647,431 | 931,637 | 692,401 |
| Net Cash from / (used in) Investing Activities | -- | (1,106,121) | (527,282) | (858,737) | 1,563,266 |
| Net Cash from / (used in) Financing Activities | -- | 582,948 | 51,808 | (5,789,766) | 4,475,544 |
| Increase / (Decrease) in Cash & Cash Equivalents | -- | 1,518,029 | 1,171,957 | (5,716,866) | 6,731,211 |
| Cash & Cash Equivalents at beginning of period | -- | 2,503,999 | 1,330,951 | 7,103,000 | 367,805 |
| Effect of Foreign Exchange Rate Changes | -- | 8,179 | 1,091 | (55,183) | 3,984 |
| Others | -- | 0 | 0 | 0 | 0 |
| Cash & Cash Equivalents at end of period | -- | 4,030,207 | 2,503,999 | 1,330,951 | 7,103,000 |
| Remarks: | Real time quote last updated: 07/11/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,182,083 |
| %Change | 20.233% |
| EPS / (LPS) | RMB 1.140 |
| NBV Per Share (¥) | RMB 8.569 |